Novartis
4Q Revenues: $12.9 billion (+5%)
4Q Earnings: $2.0 billion (+111%)
FY Revenues: $49.1 billion (+1%)
FY Earnings: $7.7 billion (+15%)
Comments: Innovative medicines sales were $8.8 billion in the quarter, up 6%. Growth in the quarter was driven by Cosentyx (up 57% to $615 million) and Entresto (up 172% to $185 million), partly offset by the negative impact of generic competition and pricing. Gleevec/Glivec sales were down 41% to $448 million impacted by generic competition. Tasigna sales were $485 million in the quarter, up 6%. Sandostatin sales were $421 million, up 3%. Afinitor/Votubia sales were $407 million, up 4%. Exjade sales were up 19% to $281 million. Tafinlar + Mekinist sales were up 38% to $246 million. Ultibro sales were $120 million, up 33%. Xolair sales were $247 million, up 14%. Gilenya sales were $825 million, up 2%. Earnings growth in the quarter was driven by income from associated companies, which amounted to $416 million compared to $156 million in 4Q16. The increase was mainly due to higher income recognized from the company’s investment in GSK Consumer Healthcare Holdings Ltd.